Objective:To investigate the the clinical curative effect of chemotherapy of GP combined with sequen-tial administration of artesunate in non - small cell lung cancer. Methods:The 113 patients with advanced non - small cell lung cancer were randomly divided into simple chemotherapy group(n = 57)and combined artesunare with chem-otherapy group(n = 56). The two groups were treated with continuous chemotherapy for 4 to 6 courses. According to the recent curative effect,the time of tumor progression and survival rate in 1 year,the clinical curative effects were compared between the two groups. Results:There was no statistical difference in age,gender,tumor staging in the two groups. The end of chemotherapy after treatment,the effective rates of the two groups had no significant difference. The control rate of test group was 78. 60% higher than the control group 61. 40%(P ﹤ 0. 05). The time of tumor progres-sion in experimental group[(7. 8 ± 3. 8)months]was longer than that of the control group[(6. 0 ± 3. 4)months](P﹤ 0. 05);The 1 year survival rate in the experimental group(41. 10% )was higher than that of the control group (22. 80% )(P ﹤ 0. 05). Conclusion:The treatment of chemotherapy combined with sequential administration of arte-sunate can improve the disease control rate,prolong the time to tumor progression and survival rate in 1 year in pa-tients with non - small cell lung cancer.%目的：探讨 GP 方案化疗联合青蒿琥酯序贯给药对晚期非小细胞肺癌（ non - small cell lung cancer， NSCLC）患者的临床疗效和生存时间影响。方法：采用随机对照研究的方法，将113例 NSCLC 患者分成两组。对照组57例，予单纯化疗（GP 方案：吉西他滨＋顺铂）；试验组56例，予化疗联合青蒿琥酯序贯治疗，化疗前2天开始口服多糖铁复合物胶囊（力蜚能）（150mg，qd，共10天）；两组均连续化疗4-6个疗程，停药后追踪观察2年。根据各组化疗后的近期疗效、肿瘤进展时间、1年生存率，比较两组的临床疗效。结果：两组入选的患者，在年龄、性别、肿瘤分期等方面无统计学差异，化疗结束后两组的治疗有效率无明显差异，试验组的疾病控制率为78.60％，高于对照组的61.40％（P ﹤0.05）。试验组的肿瘤进展时间[（7.8±3.8）个月]长于对照组[（6.0 ± 3.4）个月]（P ﹤0.05）。试验组的 1年生存率（41.10％）高于对照组（22.80％）（P ﹤0.05）。结论：化疗联合青蒿琥酯序贯给药能提高 NSCLC 患者化疗后的疾病控制率，延长肿瘤进展时间及 1年生存率。
展开▼
